Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06775964 · ClinicalTrials.gov registry record · Phase 1
Stem Cell Therapy for Early Alzheimer's Disease
A Phase 1 study of Cognitive Dysfunction, sponsored by Paul E Schulz.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT06775964: Recruiting Phase 1 study of Cognitive Dysfunction, sponsored by Paul E Schulz.
NCT06775964 is a Phase 1 study of Cognitive Dysfunction that is actively recruiting participants, run by Paul E Schulz. The registered enrollment target is 12 participants, below the 1,993-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06775964, a Phase 1 study of Cognitive Dysfunction, is actively recruiting participants, sponsored by Paul E Schulz.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participants, so they are their own donor. The main questions this trial aims to answer are: * Does stem cell therapy reduce inflammation in the brain? * Does stem cell therapy improve brain activity? * Does stem cell therapy slow down progression to Alzheimer's disease? Participants will: * Have a small fat biopsy taken at a doctor's office to process stem cells * Receive 4 infusions of stem cells, through a vein in the arm over 12 weeks * Visit the clinic every 2-4 weeks for the first 4 months and then every 1-2 months for 8 months for checkups and tests
Primary Outcome
Level of TSPO PET tracer will be measured for each PET scan. TSPO positivity, which is a marker for activated microglia, correlates with neuroinflammation
Conditions Studied
Interventions
- BIOLOGICAL adMSC
Study Locations (1)
Texas
- The University of Texas Health Science Center at Houston (UTHealth) - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-02 |
| Est. Completion | 2027-01 |
| Phase | Phase 1 |
What NCT06775964 shows while recruiting
NCT06775964 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 1,993-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower).
The record links to 1 condition, with Cognitive Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which adMSC is the first listed.
NCT06775964 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06775964 about?
NCT06775964 is a clinical study titled "Stem Cell Therapy for Early Alzheimer's Disease". The goal of this clinical trial is to learn if stem cell therapy works to treat brain inflammation in adults. Inflammation in the brain may be involved in adults who have memory or thinking problems. The stem cells will be taken from participant's fat samples, processed and given back to participant...
What is the current status of trial NCT06775964?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-02. Estimated completion is 2027-01.
What conditions does trial NCT06775964 study?
This clinical trial studies the following conditions: Cognitive Dysfunction.
What interventions are being tested in trial NCT06775964?
The interventions under investigation include: adMSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT06775964?
This trial is sponsored by Paul E Schulz, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06775964 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cognitive Dysfunction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06775964's enrollment target sits among peer trials
12 42nd of 45 higher than 3 of 45 other Cognitive Dysfunction trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Cognitive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Cognitive Rehabilitation for Veterans With MDD-related Cognitive Functioning Deficits
RECRUITING · NA
-
Surviving Daily Life
RECRUITING
-
The Better, Harder, Faster, Stronger Study
RECRUITING
-
Network-targeted Theta-burst Stimulation for Episodic Memory Improvement in Mild Cognitive Impairment
RECRUITING · NA
-
Sleep Healthy Using the Internet Mitigating Insomnia to Address Neurocognitive Difficulties (SHUTi MIND)
RECRUITING · Phase 2
-
High-Intensity Exercise to Combat Vascular and Cognitive Dysfunction in Adults With HIV
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia